GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma

NCT05335018 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/refractory Diffuse Large B Cell Lymphoma

Interventions

DRUG: Glofitamab, Poseltinib, Lenalidomide

Sponsor

Seoul National University Hospital